Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6015404 | Epilepsy Research | 2015 | 8 Pages |
Abstract
During adjunctive stiripentol use with clobazam and valproate, careful monitoring for adverse events such as somnolence and loss of appetite is recommended, and dose reduction may become needed for any of the antiepileptics. Despite the need for safety precautions, the durable responses to stiripentol for up to 56 weeks suggest that the drug is effective as an adjunct to clobazam and valproate for the treatment of Dravet syndrome.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Yushi Inoue, Yoko Ohtsuka, STP-1 Study Group STP-1 Study Group,